• Synchron next-generation implantable BCI, powered by NVIDIA Holoscan, showcased at 2025 JP Morgan Healthcare Conference

Synchron to Advance Implantable Brain-Computer Interface Technology with NVIDIA Holoscan

Media
Kimberly Ha
Synchron
kha@synchron.com

Synchron, a category-defining brain-computer interface (BCI) company, announced today a step forward in implantable BCI technology to drive the future of neurotechnology. Synchron’s BCI technology, in combination with the NVIDIA Holoscan platform, is poised to redefine the possibilities of real-time neural interaction and intelligent edge processing.

Synchron will leverage NVIDIA Holoscan to advance a next-generation implantable BCI in two key domains. First, Synchron will enhance real-time edge AI capabilities for on-device neural processing, improving signal processing and multi-AI inference technology. This will reduce system latency, bolster privacy, and provide users with a more responsive and intuitive BCI experience. NVIDIA Holoscan provides Synchron with: (i) a unified framework supporting diverse AI models and data modalities; (ii) an optimized application framework, from seamless sensor I/O integration, GPU-direct data ingestion, to accelerated computing and real-time AI.

Second, Synchron will explore the development of a groundbreaking foundation model for brain inference. By processing Synchron’s neural data on an unprecedented scale, this initiative will create scalable, interpretable brain-language models with the potential to transform neuroprosthetics, cognitive expression, and seamless interaction with digital devices.

“Synchron’s vision is to scale neurotechnology to empower humans to connect to the world, and the NVIDIA Holoscan platform provides the ideal foundation,” said Tom Oxley, M.D., Ph.D., CEO & Founder, Synchron. “Through this work, we’re setting a new benchmark for what BCIs can achieve.”

About Synchron

Synchron is the leading implantable brain-computer interface company, pioneering neurotechnology designed to restore functionality for individuals with paralysis by expanding autonomy. Since 2019, Synchron has completed two human clinical trials and is now preparing for a larger-scale clinical study with a device optimized for scalable manufacturing. The company has an exclusive partnership with flexible MEMs manufacturer Aquandas, ensuring access to cutting-edge technology for their innovative devices. The BCI market represents a $400 billion opportunity (Morgan Stanley report), and Synchron is at the forefront, defining the category and pushing the boundaries of what’s possible in neuroprosthetics and digital autonomy. Headquartered in New York City, Synchron is shaping the future of neurotechnology. For more information, visit www.synchron.com and follow us @synchroninc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113376337/en/